Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma

Wang, Xi; Zhang, Cheng-Sheng; Dong, Xu-Yuan; Hu, Yuan; Duan, Bao-Jun; Bai, Jun; Wu, Yin-Ying; Fan, Lin; Liao, Xin-Hua; Kang, Ye; Zhang, Peng; Li, Meng-Yang; Xu, Jiao; Mao, Zhi-Jun; Liu, Hui-Tong; Zhang, Xiao-Long; Tian, Li-Fei; Li, En-Xiao

Published in

Baishideng Publishing Group, World Journal of Gastrointestinal Oncology, 7(14), p. 1252-1264, 2022

DOI: 10.4251/wjgo.v14.i7.1252

Tools

Export citation

Search in Google Scholar

Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma

Journal article published in 2022 by Xi Wang, Cheng-Sheng Zhang, Xu-Yuan Dong, Yuan Hu, Bao-Jun Duan, Jun Bai, Yin-Ying Wu, Lin Fan, Xin-Hua Liao, Ye Kang, Peng Zhang, Meng-Yang Li, Jiao Xu, Zhi-Jun Mao, Hui-Tong Liu and other authors.

This paper is made freely available by the publisher.

Full text: Download

Preprint: archiving forbidden

Postprint: archiving forbidden

Published version: archiving allowed

Upload

Policy details

Data provided by

Published in

Links

Tools

Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma